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Currently,  26ｵ of Japanese women in their twenties are under weight,  and therefore at risk of devel-
oping various metabolic abnormalities due to an inadequate nutrient intake,  which in turn aﬀects the 
acquisition of a peak bone mineral density (BMD).  In this study,  we aimed to clarify the eﬀects of 
menstrual cycle-related changes in body weight and bone metabolic marker levels on the BMD 
changes.  The subjects were 42 women (19.6±0.8 years).  The levels of osteocalcin (OC),  BAP,  s-NTx,  
u-DPD,  and E2 in the menstrual and ovulatory phases were measured.  The associations between 
dependent variables (BMD changes/year in the lumbar spine,  femur,  femoral neck) and explanatory 
variables (body weight changes/year,  the levels of OC,  BAP,  s-NTx,  u-DPD) were evaluated using 
multiple regression analysis.  Analysis of the correlations between the changes in bone metabolic mark-
ers and changes in BMD showed a correlation between the OC level in the menstrual phase and 
changes in the BMD of the entire femur,  suggesting that a high OC level protects against BMD reduc-
tion,  probably by promoting osteoblast activity,  and that bone formation activity suppresses the 
decrease in BMD.  These results suggest that,  to predict BMD changes from bone metabolic markers 
in young women,  it is necessary to measure OC levels in the menstrual phase.
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steoporosis is an important issue in Japan,  
which is fast becoming a “super-aging” society.  
Unfortunately,  the current osteoporosis treatment 
does not lead to reacquisition of suﬃcient bone mass.  
At the present time,  a physiological increase in bone 
mass can be expected only in adolescence.  Moreover,  
suﬃcient bone mass in adolescence can only be assured 
by adequate osteoporosis education eﬀorts [1,  2].  
The acquisition of a high peak bone mass (PBM) in 
youth is considered necessary [3].  A suﬃcient bone 
mass in this period is considered an eﬀective preven-
tive method for osteoporosis.  Various studies on 
changes in the bone mass in young people have been 
performed [4-7].  The inﬂuence on PBM of a recent 
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thinness trend among youth is considered problematic 
[8],  particularly since even short-term extreme diets 
can result in a long-term reduction of bone mass [9].  
According to the 2002 National Nutrition Survey,  
26ｵ of Japanese women in their 20s were under 
weight (BMI＜18.5),  and the rate was found to have 
doubled over 2 decades.  Many of these women evalu-
ate themselves as “fat” even though their BMI is low.  
They are in a state of low energy availability,  insuﬃ-
cient nutrient intake,  and unbalanced eating habits due 
to extreme diets that often involve skipping meals.  
Moreover,  the intakes of trace nutrients,  such as 
calcium,  iron,  copper,  and zinc,  are below the required 
levels ＜http://www. mhlw. go. jp/houdou/2003/12/ 
h1224-4. html＞(accessed June 21,  2010).  Under such 
conditions,  various metabolic abnormalities occur in 
the body and inﬂuence the PBM.  Grinspoon et al.  
[10] reported that bone mass was markedly reduced 
in women with thinness oriented eating habits,  and,  in 
addition to estrogen insuﬃciency,  being under weight 
was an important factor in bone mass reduction.  It has 
been shown that a low body weight aﬀects the bone 
mineral density (BMD),  but no association has been 
demonstrated between longitudinal changes of body 
weight and BMD.
　 Furthermore,  estrogen secretion in the female 
body controls bone metabolism,  and a decrease in 
estrogen secretion leads to reduced levels of bone 
formation markers and increased levels of bone 
resorption markers [11-18].  Accordingly,  bone 
metabolism is controlled by female sex hormone 
release,  and the reduction of this release lowers the 
bone formation marker levels and elevates the bone 
resorption marker levels,  leading to bone destruction 
surpassing bone formation and subsequent BMD 
reduction.
　 The guidelines for the appropriate use of bone 
metabolic markers were revised in 2004 by the Japan 
Osteoporosis Society Exploratory Committee [19].  
However,  our previous study showed that menstrual 
cycle-related changes of estrogen levels were related 
to changes in bone formation marker levels in men-
struating young women [20].  Therefore,  it is neces-
sary to identify the menstrual cycle phase before 
measuring the bone metabolic markers,  and then to 
investigate the association between the bone metabolic 
markers and BMD reduction.
　 For all of these reasons,  the acquisition of BMD 
is crucial in young women who have begun menstrua-
tion.  And thus it is important to detect BMD changes 
in young women promptly,  in order to promote osteo-
porosis prevention.  In this study,  we investigated the 
association between changes of menstrual cycle-
related estrogen levels and bone metabolic marker 
levels in young women.  In addition,  we conducted a 
1-year longitudinal study to investigate the eﬀects of 
changes of body weight and bone metabolic markers on 
BMD changes in the menstrual and ovulatory phases.
Materials and Methods
　 Subjects. Subjects were young women recruited 
from among 1st-3rd year university students in 
Hiroshima Prefecture.  The study content and method 
were suﬃciently explained to all subjects,  and written 
consent was obtained before the study.  Eighty-two of 
84 participants in the explanatory meeting provided 
consent and underwent the survey.  Of the 67 subjects 
who participated in the survey in 2004 and 2005 and 
underwent all biochemical tests in both the menstrual 
and ovulation phases,  42 subjects aged 19.6±0.8 
years were classiﬁed as having a normal menstrual 
cycle,  deﬁned as a cycle of 23-38 daysʼ duration based 
on the cumulative menstrual cycle pattern reported by 
Treloar et al. [21].  and Mishell [22],  and these subjects 
were included in analysis.  This study was conducted 
in accordance with the Declaration of Helsinki after 
approval by the Ethics Committee of Fujita Health 
University School of Medicine (#07-140).
　 Measurements. An interview and measurements 
of physical characteristics,  BMD,  and biochemical 
parameters were conducted.  The menstrual phase was 
determined through self-reporting during the inter-
view.  The ovulation phase was also determined in the 
interview,  and conﬁrmed by the observation of fern-
like crystals in the subjectʼs saliva under a micro-
scope.  As physical characteristics,  the body weight 
and height were measured.  The BMD (g/cm2) was 
measured in the lumbar vertebra (L2-L4),  left femo-
ral neck,  and entire left femur using an X-ray BMD 
measurement system (QDR-4500; Hologic,  Bedford,  
MA,  USA).  Calibration of this BMD system was 
performed 99 times during the survey period,  and the 
mean BMD,  SD,  and c.v.  were 1.038g/cm2,  
0.003g/cm2,  and 0.37ｵ,  respectively,  which were in 
the normal reference range,  based on the data pro-
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vided by HOLOGIC Inc.  As the biochemical parame-
ters we measured 2 bone formation markers,  serum 
osteocalcin (OC) and serum bone-speciﬁc alkaline 
phosphatase (BAP),  and 2 bone resorption markers,  
serum type I collagen-crosslinked peptide (s-NTx) and 
urinary deoxypyridinoline (u-DPD).  We also studied 
blood estradiol (E2).  Blood and urine were collected 
in the menstrual and ovulation phases.  Serum samples 
for OC,  BAP,  s-NTx,  and E2 measurement were 
prepared by centrifuging blood at 1,500×g for 10min.  
For u-DPD measurement,  the 2nd morning urine was 
collected and centrifuged at 500×g for 5min,  and the 
supernatant was stored at －20℃.  These biochemical 
measurements were performed by SRL Inc.  (Tokyo.  
Japan) using commercially available kits.  Table 1 
shows the normal ranges of the biochemical parame-
ters.
　 Outcome. The changes in the BMD of the 
lumbar spine,  femoral neck,  and entire femur were 
obtained by subtracting their BMD values measured 
in 2004 from those measured in 2005.  Data were 
tested for normal distribution using the Kolmogorov-
Smirnov test.  The p-values for the lumbar spine,  
femoral head,  and entire femur were 0.200,  0.102,  
and 0.200,  respectively,  indicating a normal distribu-
tion (p＞0.005).
　 Data analysis. The data are presented as the 
means±standard deviation.  The changes over a one-
year period were deﬁned as the values for 2005 minus 
those for 2004.  The diﬀerences in the OC,  BAP,  
s-NTx,  u-DPD,  and E2 levels between the menstrual 
and ovulation phases were analyzed by employing a 
paired t-test.  The correlations among the body weight 
values in 2004,  body weight changes over a one-year 
period,  change of lumbar spine BMD,  femoral neck 
BMD,  entire femur BMD for a year (g/cm2),  and the 
levels of OC,  BAP,  s-NTx,  u-DPD and E2 in the 
menstrual and ovulation phases were tested using 
Pearsonʼs correlation coeﬃcients.  Multiple regres-
sion analysis was performed using outcome variables 
as dependent variables,  and the body weight in 2004,  
body weight changes over a one-year period,  and the 
levels of OC,  BAP,  s-NTx,  u-DPD,  and E2 as 
explanatory variables to examine the associations 
between the variables.  The correlations between the 
body weight in 2004,  body weight changes over a one-
year period,  and the levels of OC,  BAP,  s-NTx,  
u-DPD and E2 in the menstrual and ovulatory phases 
were investigated.  No strong correlation (0.7 or 
higher,  p＜0.001) was noted in any combination of 
these parameters.  In addition,  the body weight in 
2004 was adjusted as a confounding factor of the 
multiple regression analysis,  because we considered 
that the BMD would likely be increased by the burden 
of additional body weight [23-26].  Residual errors of 
the multiple regression analysis were tested for nor-
mal distribution using the Kolmogorov-Smirnov test.  
The p-values for the lumbar spine,  femoral head,  and 
entire femur were 0.200,  0.072,  and 0.200,  respec-
tively,  indicating a normal distribution in the men-
strual phase (p＞0.005).  The p-values for the lumbar 
spine,  femoral head,  and entire femur were 0.200,  
0.074,  and 0.102,  respectively,  indicating a normal 
distribution in the ovulation phase (p＞0.005).  
Probability values of 0.05 or lower were regarded as 
statistically signiﬁcant in all tests.  Statistical analysis 
was performed using SPSS16.0J software (SPSS 
Japan Inc.,  Tokyo,  Japan).
Results
　 The physical characteristics of the subjects are 
shown in Table 2.  The subjects were 157.0±4.9cm in 
height and 51.8±6.0kg in body weight.  These values 
were not signiﬁcantly diﬀerent from those in the 2004 
Survey on the Trends of National Health.  The body 
weight and BMD of the femoral neck in 2005 were 
signiﬁcantly lower than those in 2004.  The BMD of 
the lumbar spine,  femoral neck,  and entire femur 
varied in the range of －0.049-0.05,  －0.106-0.023,  
and －0.078-0.122,  respectively.
　 On comparison of the bone metabolic markers in 
2004 between the menstrual and ovulation phases,  the 
u-DPD level was signiﬁcantly lower in the ovulation 
phase than in the menstrual phase (p＝0.002),  while 
the E2 level was signiﬁcantly higher in the ovulation 
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Table 1　 Normal ranges of biochemical parameters
biochemical parameters reference value
OC (ng/ml) 3.1-12.7
BAP (U/l) 9.6-35.4
s-NTx (nmol BCE/l) 7.5-16.5
u-DPD (nmol/mmol・Cr) 2.8-7.6
E2 (pg/ml) menstrual periods　　 10-78
ovulation periods　　103-366
phase (p＜0.001),  but no signiﬁcant diﬀerences were 
noted in the OC,  BAP,  or s-NTx level between the 
phases (Table 3).
　 Correlations among the bone metabolic markers in 
the menstrual and ovulation phases are shown in Table 
4.  In the menstrual phase,  signiﬁcant positive corre-
lations were detected between the OC and BAP level 
(r＝0.424,  p＝0.005) and between the OC and s-NTx 
level (r＝0.332,  p＝0.031),  and a signiﬁcant negative 
correlation was noted between the u-DPD and E2 
level (r＝－0.415,  p＝0.006).  In the ovulation phase,  
signiﬁcant positive correlations were noted between 
the OC and BAP level (r＝0.341,  p＝0.027) and 
between the u-DPD and E2 level (r＝0.349,  p＝0.023).
　 Table 5 shows the results of multiple regression 
analysis using the body weight changes over a one-year 
period and levels of OC,  BAP,  s-NTx,  and u-DPD in 
the menstrual and ovulatory phases as explanatory 
variables,  and BMD changes as dependent variables.  
In the menstrual phase,  the BMD of the femoral neck 
was signiﬁcantly correlated with the changes of body 
weight over a one-year period (β＝0.355,  p＝0.041),  
and that of the entire femur was signiﬁcantly corre-
lated with the OC level (β＝0.463,  p＝0.012).  In the 
ovulation phase,  the BMD of the femoral neck was 
signiﬁcantly correlated with the changes of body 
weight over a 1-year period (β＝0.371,  p＝0.032).
Discussion
　 We compared the E2 and bone metabolic marker 
levels between the menstrual and ovulation phases in 
healthy young women aged about 20 years.  The E2 
and u-DPD levels were signiﬁcantly diﬀerent between 
the 2 phases.  The ovulation phase was identiﬁed by 
observing fern-like crystals in saliva under a micro-
scope.  Cervical mucus alters during the ovulation 
phase and fern-like crystals are observed in saliva 
[27].  In menstruating women,  E2 secretion increases 
immediately before ovulation,  which promotes ovarian 
follicular development.  Secretion slowly decreases 
thereafter,  entering the menstrual phase.  The diﬀer-
ence in the E2 level between the menstrual and ovula-
tion phases validated the identiﬁcation of the men-
strual phase based on menstrual bleeding reported by 
the subjects and that of the ovulation phase by observ-
ing fern-like crystals in saliva.  However,  the standard 
deviation of the E2 level in the ovulation phase was a 
high value.  This was thought to be because identiﬁca-
tion of the ovulation phase by observation of fern-like 
crystals is subject to error for several days before and 
after the date of ovulation [28].  Identiﬁcation of the 
date of ovulation thus requires measurement of the 
basal body temperature and luteinizing hormone.  
However,  these measurements were not performed,  
since they are generally not included in infertility or 
pregnancy surveys like those used in the present 
study.  This is a limitation inherent in identiﬁcation of 
the ovulation phase based on the observation of fern-
like crystals i.e.,  the method used in this study.  The 
u-DPD level decreases with elevation of the carboxy-
terminal propeptide of type I procollagen (PICP),  a 
bone formation marker,  4 days after the E2 level 
peaks in the ovulation phase [29],  because osteo-
blasts possess estrogen receptors and estrogen pro-
motes collagen synthesis [12,  13].  Zittermann et al. 
[30] reported that ovulation-related elevation of the 
estrogen level elevated the PICP level and resulted in 
a low u-DPD level,  suggesting that estrogen directly 
inﬂuences bone metabolism by stimulating osteoblasts 
and inhibiting osteoclasts.  No changes in the BAP and 
OC levels during the menstrual cycle have been 
reported [13],  which is consistent with our ﬁndings.  
Regarding the s-NTx level,  we previously reported its 
usefulness for the evaluation of bone resorption in 
premenopausal women as an index not inﬂuenced by the 
menstrual cycle [20].
　 Positive correlations were noted between the BAP 
and OC levels in the menstrual and ovulation phases.  
BAP is an enzyme abundant in osteoblasts [31].  It 
reﬂects bone growth and its level rises in bone neo-
genesis.  OC is a calcium-binding protein accounting 
for 25ｵ of non-collagen protein in bone.  It is synthe-
sized in osteoblasts and converted to the Gla form in 
the presence of vitamin K,  which serves as an index of 
bone-forming activity.  The positive correlation between 
the BAP and OC levels may have been due to the fact 
that both are osteoblast-derived bone formation mark-
ers.  The E2 and u-DPD levels showed a signiﬁcant 
negative correlation in the menstrual phase and sig-
niﬁcant positive correlation in the ovulation phase.  
The E2 level starts to decrease 3 days before men-
struation and remains low during the menstrual phase 
[30].  E2 deﬁciency during this phase may lead to the 
proliferation of osteoclasts which have escaped from 
normal cell death in bone tissue,  thereby promoting 
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bone resorption [32].  Blumsohn et al. observed a 
strong negative correlation between E2 and bone 
metabolic markers in adolescent girls,  which was 
similar to our ﬁndings in the menstrual phase [33].  
The u-DPD level decreases with elevation of the 
PICP level,  a bone formation marker,  4 days after 
the E2 level peaks in the ovulation phase [28].  In the 
above-mentioned study of Zittermann et al. [30],  an 
ovulation-related elevation of the estrogen level ele-
vated the PICP level and resulted in a low u-DPD 
level.  Immediately after the rapid rise and peak of the 
E2 in the ovulation phase,  the E2 level decreased.  
And the u-DPD level decreased by a short time later.  
Therefore,  this study thought by positive correlation 
was shown as a result that the u-DPD level reduction 
by E2 level rise takes place in a time lag at the same 
time it decreases,  after E2 level reaches a peak.  
Based on these ﬁndings,  identiﬁcation of the men-
strual cycle phase is necessary to investigate the use-
fulness of the u-DPD level in young women.
　 Multiple regression analysis showed that the 
changes of body weight over a one-year period were 
correlated with the BMD of the femoral neck in the 
menstrual and ovulation phases.  This is also sup-
ported by the report of Lueken et al. [34] that tetra-
plegia,  postoperative bed rest,  and weightlessness in 
space ﬂight were associated with a BMD decrease.  
We consider that the load of the body weight on dif-
ferent parts of the body mechanically stimulates bones,  
thereby strengthening the microstructure of bone tis-
sue.  In particular,  the results of this study suggest 
that the BMD changes are at least partly induced by 
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Table 3　 Relationship between the menstrual cycle and bone metabolic markers in 2004
Menstrual phases Ovulatory phases
mean SD min - max mean SD min - max p value
OC (ng/ml) 6.1 (1.9) 2.7 - 9.1 6.0 (2.2) 1.0 - 10.9 0.731
BAP (U/l) 24.1 (8.0) 12.5 - 46.4 24.0 (8.1) 13.3 - 51.5 0.954
s-NTX (nmolBCE/l) 10.0 (2.4) 7.1 - 18.7 10.9 (3.0) 6.9 - 19.4 0.134
u-DPD (nmol/mmol・CRE) 7.7 (2.2) 3.3 - 13.5 6.8 (1.7) 3.6 - 12.7 0.002
E2 (pg/ml) 24.5 (15.4) 8.0 - 76.0 87.2 (66.4) 24.0 - 331.0 ＜0.001
Table 5　 Multivariate linear regression analysis of the change of BMD over one year (lumbar spine, femoral neck, entire femur)
〔A〕menstrual phases
Change of lumbar spine BMD Change of femoral neck BMD Change of entire femur BMD
β p R2 β p R2 β p R2
Change of body weight for a year (kg/y) 　0.166 0.345 0.158 　0.355 0.041 0.223 　0.076 0.651 0.230
OC (ng/ml) 　0.171 0.359 　0.025 0.889 　0.463 0.012
BAP (U/l) －0.253 0.180 　0.104 0.561 －0.015 0.935
s-NTX (nmolBCE/l) －0.023 0.890 －0.072 0.646 　0.110 0.484
u-DPD (nmol/mmol・CRE) 　0.014 0.943 －0.075 0.681 －0.003 0.986
E2 (pg/ml) 　0.033 0.864 －0.199 0.287 －0.112 0.544
〔B〕ovulatory phases
Change of lumbar spine BMD Change of femoral neck BMD Change of entire femur BMD
β p R2 β p R2 β p R2
Change of body weight for a year (kg/y) 　0.193 0.267 0.162 　0.371 0.032 0.210 　0.145 0.406 0.140
OC (ng/ml) －0.169 0.354 －0.024 0.892 －0.041 0.825
BAP (U/l) －0.065 0.716 　0.070 0.684 －0.003 0.986
s-NTX (nmolBCE/l) －0.080 0.641 －0.003 0.985 －0.101 0.562
u-DPD (nmol/mmol・CRE) 　0.042 0.803 　0.038 0.816 　0.319 0.068
E2 (pg/ml) －0.222 0.221 　0.147 0.402 －0.202 0.271
※adjustment for the body weight in 2004
the body weight change in daily life,  and that the loss 
of body weight decreases the BMD.  Accordingly,  the 
maintenance of an appropriate body weight greatly 
aids in the prevention of osteoporosis in young women 
who are prone to prioritize their desire for slimness.  
Nonetheless,  further research in this area will be 
needed,  since the present work had a study period of 
only one year and the statistical signiﬁcance was par-
ticularly strong (p＝0.025－0.028).  Meanwhile,  based 
on the results of mouse studies in which BMD changes 
were accompanied by a body weight change,  it has 
been speculated that leptin regulates the bone mass via 
a balance between an indirect action through the ner-
vous system [35,  36] and a direct action on osteo-
clasts [37].  The epidemiological survey performed a 
cross-sectional study for men and women reported a 
positive correlation between blood leptin levels and the 
BMD [38-40].  Therefore,  the present ﬁnding of a 
BMD change accompanied by a body weight change was 
tentatively attributed to changes in BMD due to the 
load of the body weight,  as well as the regulation of 
bone mass by leptin.  In order to clarify this result,  it 
is necessary to measure leptin levels on a continuous 
basis in a longer-term study.
　We studied the bone metabolic markers in 2004 and 
BMD in the following year to investigate the inﬂuence 
of the markers on the BMD.  In the menstrual phase,  
the OC level was correlated with the BMD of the 
entire femur,  suggesting that a high OC level in the 
menstrual phase is associated with an increase in the 
BMD.  It has been shown that the BAP level increases 
earlier than the OC level in the ﬁrst menstruation 
because it reﬂects bone growth more markedly than 
OC [41].  However,  its variation tends to decrease 
after the ﬁrst menstruation [42],  and it is unclear 
whether it reﬂects the condition of bone formation in 
adult women.  This study suggested that the OC level 
serves as a preventive factor against BMD reduction 
and reﬂects osteoblast activity,  and the bone-forming 
activity inhibits BMD reduction.  In contrast,  no sig-
niﬁcant association was observed between the bone 
metabolic markers and BMD in the ovulation phase,  
which may have been due to the fact that bone meta-
bolic turnover is inﬂuenced several days after the 
female sex hormone level rises [29].  Therefore,  to 
predict BMD changes by measuring bone metabolic 
markers in young women,  the OC level in the men-
strual phase should be measured.
　 The physiques of the subjects were close to the 
age-matched means [43] in other surveys in Japan as 
well as those in subjects excluded from this survey,  
suggesting that the ﬁndings are valid for application to 
young women in general.  The limitations of this study 
are that the subjects were female college students who 
participated in a health survey including BMD mea-
surement,  and therefore might have been biased 
toward those who were in good health or had marked 
health awareness.  Furthermore,  although this study 
was performed over a short period of 1 year,  some 
young subjects showed a BMD change of about 10ｵ 
during that period.  Although the cv (＝0.3ｵ) of the 
equipment suggests the presence of errors,  we con-
sider that the BMD changes during the year were 
accurately detected.  However,  longitudinal investiga-
tion involving broader populations will be needed 
before our results can be generalized to the population 
at large.
　 In conclusion,  we examined the association between 
the changes in female hormone levels and bone meta-
bolic markers during the menstrual cycle in 42 healthy 
young women,  aiming to clarify the eﬀects of men-
strual cycle-related changes in the body weight and 
bone metabolic marker levels on the changes in BMD.  
The E2 level was signiﬁcantly higher in the ovulation 
than in the menstrual phase,  while the u-DPD level 
was signiﬁcantly lower in the ovulation phase.  The OC 
and BAP levels showed signiﬁcant positive correla-
tions in both the menstrual and ovulation phases.  The 
E2 and u-DPD levels were negatively correlated in the 
menstrual phase,  and positively correlated in the 
ovulation phase.  The E2 levels in the menstrual 
phases suggested that estrogen directly inﬂuences 
bone metabolism by stimulating osteoblasts and inhib-
iting osteoclasts.  In addition,  this study thought by 
positive correlation in ovulation phases was shown as 
a result that the u-DPD level reduction by the 
increase in E2 levels takes place in a time lag at the 
same time it decreases,  after E2 level reaches a peak.  
Analysis of the correlations between bone metabolic 
markers and BMD changes showed a correlation 
between the OC level and changes in the BMD of the 
entire femur in the menstrual phase.  Based on these 
ﬁndings,  to predict BMD changes by measuring bone 
metabolic markers in young women,  the OC level in 
the menstrual phase should be employed.  The changes 
in the body weight over 1 year were correlated with 
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the changes in the BMD of the femoral neck in the 
menstrual and ovulatory phases,  suggesting that a 
higher body weight leads to a heavier load on the 
femoral neck,  thereby inhibiting the decrease in BMD.  
However,  our results did not provide evidence of a 
change in the bone resorption by estrogen,  since there 
was no correlation between E2 and BMD in the multi-
variate analysis.  This study was limited in that it was 
performed over a short period of 1 year,  and because 
the subject group was biased toward female college 
students who had high-level health awareness.  Thus,  
a long-term longitudinal study of a larger population of 
subjects is still needed.
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